# 5-jaarsfollow-up van intracoronaire celtherapie na MI: REGENERATE-AMI

*geplaatst 2022-04-01 · Algemeen · ESC heart failure · doi 10.1002/ehf2.13786 · https://hartvaat.nl/2022/04/01/5-jaarsfollow-up-van-intracoronaire-celtherapie-na-mi-regenerate-ami/*

REGENERATE-AMI 5-jaarsfollow-up van intracoronaire autologe celtherapie na acuut MI.

## English: Five-year follow-up of intracoronary autologous cell therapy in acute myocardial infarction: the REGENERATE-AMI trial.

The 5-year REGENERATE-AMI follow-up showed no sustained improvement in cardiac function from intracoronary autologous bone marrow cell therapy after acute MI, adding to the long-term negative evidence for post-infarction stem cell treatment.

## Abstract (original, from the publication)

AIMS: The long-term outcomes of the intracoronary delivery of autologous bone marrow-derived cells (BMCs) after acute myocardial infarction are not well established. Following the promising 1 year results of the REGENERATE-AMI trial (despite it not achieving its primary endpoint), this paper presents the analysis of the 5 year clinical outcomes of these acute myocardial infarction patients who were treated with an early intracoronary autologous BMC infusion or placebo. METHODS AND RESULTS: A 5 year follow-up of major adverse cardiac events (defined as the composite of all-cause death, recurrent myocardial infarction, and all coronary revascularization) and of rehospitalization for heart failure was completed in 85 patients (BMC n = 46 and placebo n = 39). The incidence of major adverse cardiac events was similar between the BMC-treated patients and the placebo group (26.1% vs. 18.0%, P = 0.41). There were no cases of cardiac death in either group, but an increase in non-cardiac death was seen in the BMC group (6.5% vs. 0%, P = 0.11). The rates of recurrent myocardial infarction and repeat revascularization were similar between the two groups. There were no cases of rehospitalization for heart failure in either group. CONCLUSION: This 5 year follow-up analysis of the REGENERATE-AMI trial did not show an improvement in clinical outcomes for patients treated with cell therapy. This contrasts with the 1 year results which showed improvements in the surrogate outcome measures of ejection fraction and myocardial salvage index.

Auteurs: Anthony Mathur, Doo Sun Sim, Fizzah Choudry, Jessry Veerapen, Martina Colicchia, Tymoteusz Turlejski, Mohsin Hussain, Stephen Hamshere, Didier Locca, Roby Rakhit, Tom Crake, Jens Kastrup, Samir Agrawal, Daniel A Jones, John Martin

---
Bron: ESC heart failure, https://doi.org/10.1002/ehf2.13786. Bijgewerkt 2026-07-03T13:28:47Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.